Hypertension Management in Patients with Chronic Kidney Disease

First-Line Agent Selection

The American College of Cardiology recommends ACE inhibitors or ARBs as the preferred initial agents for patients with chronic kidney disease, as they provide renal protection beyond blood pressure lowering alone 1
The European Society of Cardiology suggests starting with lisinopril 2.5-5 mg once daily or losartan 25-50 mg once daily, given the reduced GFR, as lower starting doses are required when GFR is below 60 ml/min 1

The American Heart Association recommends checking serum potassium and creatinine 1-2 weeks after initiating ACE inhibitor/ARB therapy, as hyperkalemia and acute kidney injury are the primary risks in patients with reduced GFR 2

The American College of Cardiology recommends adding amlodipine 5-10 mg daily as the second agent if blood pressure remains ≥140/90 mmHg after 3 months on optimized ACE inhibitor/ARB 2
The combination of ACE inhibitor/ARB plus calcium channel blocker provides complementary mechanisms—vasodilation and renin-angiotensin system blockade—with superior blood pressure control compared to either agent alone 2
The European Society of Cardiology suggests adding chlorthalidone 12.5-25 mg daily as the third agent to achieve guideline-recommended triple therapy if blood pressure remains uncontrolled on dual therapy 2, 3

The American Heart Association recommends avoiding loop diuretics as they are NOT first-line agents for hypertension and are reserved for volume overload states like heart failure 4
The European Society of Cardiology suggests not combining an ACE inhibitor with an ARB, as dual RAS blockade increases risks of hyperkalemia and acute kidney injury without additional cardiovascular benefit 4
Given the patient's age, the American Geriatrics Society recommends starting with lower doses and titrating gradually over 3-6 months to minimize risk of orthostatic hypotension and acute GFR decline 3

The American College of Cardiology recommends a target blood pressure of <140/90 mmHg minimum, with consideration of <130/80 mmHg if tolerated without adverse effects 1, 2
The European Society of Cardiology suggests reassessing blood pressure monthly during titration, with the goal of achieving target within 3 months of initiating or modifying therapy 1, 2
The American Heart Association recommends measuring blood pressure in both arms at the first visit and considering home blood pressure monitoring to confirm sustained hypertension and avoid white coat effect 3

The American College of Cardiology recommends not delaying treatment intensification, as stage 2 hypertension requires prompt action to reduce cardiovascular and renal risk 2
The European Society of Cardiology suggests not assuming treatment failure without first confirming medication adherence, as non-adherence is the most common cause of apparent treatment resistance 2
The American Geriatrics Society recommends monitoring for postural hypotension at each visit, as elderly patients with renal impairment are at increased risk for orthostatic symptoms 3, 4